Stokes Capital Advisors LLC Has $4.35 Million Stock Holdings in Novo Nordisk A/S (NYSE:NVO)

Stokes Capital Advisors LLC increased its holdings in Novo Nordisk A/S (NYSE:NVO - Free Report) by 358.5% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 62,602 shares of the company's stock after purchasing an additional 48,947 shares during the period. Stokes Capital Advisors LLC's holdings in Novo Nordisk A/S were worth $4,347,000 at the end of the most recent reporting period.

A number of other large investors have also recently bought and sold shares of the business. Revolve Wealth Partners LLC boosted its holdings in Novo Nordisk A/S by 8.7% during the fourth quarter. Revolve Wealth Partners LLC now owns 2,490 shares of the company's stock valued at $214,000 after acquiring an additional 200 shares during the period. abrdn plc boosted its holdings in Novo Nordisk A/S by 12.0% during the fourth quarter. abrdn plc now owns 260,169 shares of the company's stock valued at $22,304,000 after acquiring an additional 27,784 shares during the period. GHP Investment Advisors Inc. boosted its holdings in Novo Nordisk A/S by 3.9% during the fourth quarter. GHP Investment Advisors Inc. now owns 4,738 shares of the company's stock valued at $408,000 after acquiring an additional 178 shares during the period. 1900 Wealth Management LLC boosted its holdings in Novo Nordisk A/S by 11.2% during the fourth quarter. 1900 Wealth Management LLC now owns 5,975 shares of the company's stock valued at $514,000 after acquiring an additional 600 shares during the period. Finally, Strategic Financial Concepts LLC boosted its holdings in Novo Nordisk A/S by 8,384.4% during the fourth quarter. Strategic Financial Concepts LLC now owns 143,810 shares of the company's stock valued at $12,371,000 after acquiring an additional 142,115 shares during the period. 11.54% of the stock is currently owned by institutional investors.

Novo Nordisk A/S Stock Performance

NVO stock traded up $2.05 during trading on Friday, reaching $74.70. 9,535,540 shares of the stock were exchanged, compared to its average volume of 6,905,079. Novo Nordisk A/S has a twelve month low of $57.00 and a twelve month high of $148.15. The company has a market capitalization of $335.22 billion, a P/E ratio of 22.71, a price-to-earnings-growth ratio of 0.90 and a beta of 0.66. The stock has a 50 day simple moving average of $65.87 and a 200-day simple moving average of $80.54. The company has a current ratio of 0.74, a quick ratio of 0.55 and a debt-to-equity ratio of 0.62.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last posted its quarterly earnings results on Wednesday, May 7th. The company reported $0.92 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.92. Novo Nordisk A/S had a net margin of 34.81% and a return on equity of 84.68%. The firm had revenue of $11.87 billion during the quarter. As a group, sell-side analysts anticipate that Novo Nordisk A/S will post 3.84 earnings per share for the current year.

Analysts Set New Price Targets

A number of research firms have issued reports on NVO. Dbs Bank cut shares of Novo Nordisk A/S to a "sell" rating in a report on Friday, April 25th. Morgan Stanley initiated coverage on shares of Novo Nordisk A/S in a report on Wednesday, February 12th. They set an "equal weight" rating for the company. Wall Street Zen lowered shares of Novo Nordisk A/S from a "buy" rating to a "hold" rating in a research report on Friday. Hsbc Global Res raised Novo Nordisk A/S to a "strong-buy" rating in a research report on Monday, April 28th. Finally, Guggenheim downgraded Novo Nordisk A/S from a "strong-buy" rating to a "hold" rating in a research report on Thursday, April 17th. Two equities research analysts have rated the stock with a sell rating, six have issued a hold rating, four have assigned a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Hold" and a consensus price target of $128.00.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.